In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. On ...

An EDN Design Idea (DI) presented a discussion of how to increase the resolution of an ADC by adding a non-deterministic, zero-mean, Gaussian noise dither waveform to a signal to be converted; then, ...

Many noise sources can plague high-speed radio-frequency (RF) analog signal chains, making design considerations that much more challenging. Both megahertz and sub-terahertz sampling-rate converters ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

If you’re completely new to Microsoft Word, you’re probably wondering where to begin. You’ve come to the right place because we’ll get you started. From what you see in the Word window to how to save ...

An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH). The design, preclinical study and phase I dose escalation plan of a HER2 targeted ...